Thorium Norway AS Signs Five-Year radium-228 Sales Agreement with entX Limited

Thorium Norway has entered into a long-term agreement with entX Limited (Australia) for the supply of Radium-228, covering an initial five-year period with a rolling 12-month mutual termination clause. Radium-228 will serve as a critical precursor for the production of medical isotopes used in advanced cancer treatments.

"We are proud to announce our first sales agreement and deeply appreciate the excellent collaboration with entX. Our team is fully committed to ensuring the successful delivery of Radium-228," says Jan Børge Jakobsen, CEO of Thorium Norway AS.

Read Full Press Release (NTB)
Download Full Press Release (PDF)

Contact:
Jan Børge Jakobsen
CEO, Thorium Norway AS
Email: jan.jakobsen@thoriumnorway.com
Tel: +47 95753904